Eddingpharm (Cayman)

About Eddingpharm (Cayman)

Eddingpharm (Cayman) Inc. is a fully integrated biopharmaceutical company focused on the Chinese healthcare market. Founded in September 2001 by Xin Ni, who serves as the Chairman and Chief Executive Officer, the company was established to introduce high-quality medicines from around the world to China. Ni, who holds an MBA from China Europe International Business School and an undergraduate degree from Jiangsu University, has over two decades of experience in the Chinese pharmaceutical sector, which has been instrumental in the company's direction.

Headquartered in Shanghai, Eddingpharm operates a business model centered on in-licensing, marketing, developing, and distributing hospital pharmaceutical products. The company started by collaborating with global multinational corporations (MNCs) to distribute their products in China and has since evolved to acquire full product rights for a portfolio of drug assets. Its revenue is generated through the sale of these pharmaceutical products. Eddingpharm primarily serves hospitals, with its network reaching over 1,000 hospitals across China through 23 district offices as of 2010. The company focuses on several key therapeutic areas: oncology, clinical nutrition, antibiotics, respiratory system, and cardiovascular diseases.

Eddingpharm's portfolio includes a range of products acquired through strategic partnerships and acquisitions. A significant milestone was the 2019 agreement with Eli Lilly to acquire the rights in China for two legacy antibiotic medicines, Ceclor® and Vancocin®, along with a manufacturing facility in Suzhou. The company has also entered into numerous licensing and commercialization agreements, such as with Amarin for Vascepa®, a treatment for hypertriglyceridemia, and with Syndax Pharmaceuticals for entinostat, an oncology drug. In 2014, it acquired the worldwide rights to three oncology drug assets from ACT Biotech, including Telatinib, a VEGFR inhibitor for gastric cancer. The company possesses advanced manufacturing capabilities, including a facility in Suzhou, and manages a global supply chain for its products.